Communication Matters: Exploring the Intersection of Family and Practitioner End of Life Communication: Beyond the Abstract

More often than not, we take communication for granted. We mistakenly interpret the disclosure of information whether verbally (i.e., recommendation for treatment) or nonverbally (i.e., delivery of a pamphlet) as communication. While it is true that these examples are forms of communication, they also lack meaning making and a two-way relationship between parties. In few instances is communication as vital or imperative as it is in healthcare. The importance of sound, mutual communicative relationships is especially paramount within the realm of palliative and end of life care. 
Read more ...

A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors: Beyond the Abstract

The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib (CO-338; formerly known as AG-014447 and PF-01367338) has a high selectivity for PARP-1, -2, and -3 [1, 2], which play a key role in repair of single-strand DNA damage [3]. Inhibition of these enzymes can lead to accumulation of DNA double-strand breaks [4, 5]. PARP inhibitors have been shown to be selectively lethal to cells with mutations in other genes involved in DNA repair, such as BRCA1 and BRCA2 (BRCA1/2) [6-8]. Such mutations are common in various tumor types (eg, breast, ovarian), and in preclinical studies, rucaparib was cytotoxic to cells with a deleterious BRCA1/2 mutation or epigenetic silencing of BRCA1 [7, 9].
Read more ...

Psychophysical health status of breast cancer survivors and effects of 12 weeks of aerobic training: Beyond the Abstract

In a recent harmonised meta-analysis of data from more than 1 million men and women, Ekelund and colleagues [1] reported the role of physical activity in the attenuation or elimination of the detrimental association between sitting time and mortality.
Read more ...

A clinical, histologic, and follow-up study of genital melanosis in men and women: Beyond the Abstract

Genital melanosis, a rare condition often characterized by large, asymmetrical and often mutli-focal pigmentation occurring on genital skin, is often mistaken for genital melanoma. As the literature on the topic is limited, management of these patients is often very difficult as little is known about the risk for progression to gential melanoma.  Although lesions biopsied from patients with genital melanosis show benign histologic features, providers may opt for further excisional procedures due to the concerning clinical appearance of these lesions and uncertainty about future melanoma risk. 
Read more ...

Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells: Beyond the Abstract

Ovarian cancer is the deadliest among women related cancers due to problems in early detection and treatment. It is seen that initially, the cancer responds well to therapy; however, in majority of advanced cases, the ovarian tumors relapse with a resistant disease profile. 
Read more ...

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan: Beyond the Abstract

High-dose chemotherapy with single-agent melphalan followed by an autologous stem-cell transplant (ASCT) results in significant benefit as a front-line consolidation therapy for chemosensitive myeloma. In contrast, the efficacy of high-dose melphalan for relapsed or refractory myeloma is much lower, with only 5–10% of patients achieving complete remission (CR) and median progression-free survival (PFS) of about 12 months after ASCT. 
Read more ...

Use of prostatic specific antigen in primary care (PSA): Beyond the Abstract

The conclusions and the use that have surrounded the prostate-specific antigen (PSA) since its incorporation into the usual clinical practice during the 1990s have varied over the years. Like any screening tool, it should serve to detect the largest number of cases (by excess), minimizing the number of false negatives, in addition to achieving an increase in the survival of an oncological disease such as prostate cancer, considered the more prevalent solid neoplasia in Europe (1).
Read more ...
@OncToday